The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD) | Zendy

Faith E. Davies | Zendy; Pingping Wu | Zendy; Matthew Jenner | Zendy; Muralikrishnan Srikanth | Zendy; Radovan Sašo | Zendy; Gareth J. Morgan | Zendy

Open Access

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

Author(s) -

Faith E. Davies,

Pingping Wu,

Matthew Jenner,

Muralikrishnan Srikanth,

Radovan Sašo,

Gareth J. Morgan

Publication year - 2007

Publication title -

haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.782

H-Index - 142

eISSN - 1592-8721

pISSN - 0390-6078

DOI - 10.3324/haematol.11228

Subject(s) - dexamethasone , bortezomib , medicine , toxicity , cyclophosphamide , neutropenia , multiple myeloma , pharmacology , refractory (planetary science) , oncology , chemotherapy , physics , astrobiology

The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research